Real-Time PMA Supplements Should Include Risk Analysis, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Real-time PMA supplements should include a detailed risk analysis to support the continued safety and effectiveness of the modified device, FDA stresses in a guidance issued April 28